Home | Research & Innovation | Scientific Programmes | Molecular Oncology Programme | Melanoma Group
Graduate Students
- Xavier Catena
- Marta Contreras
- Guillermo De la Vega
- Naiara Juan
- Sergio Oterino
- Thelma Poluha
- José Antonio Torres
Technicians
- Tonantzin Guadalupe Calvo
- Cynthia Mucientes
- Mireia Vallespinós
Melanomas are inherently aggressive cancers for which basic and translational research have significantly improved patient prognosis. Nevertheless, clinical responses are still incomplete. The long-term goals of our Group are to identify new progression biomarkers and to validate more effective therapeutic agents. We are particularly interested in mechanisms of cellular stress that, being selectively deregulated in melanoma, define lineage-specific vulnerabilities (publications in Nature, Cancer Cell, Nature Cell Biology, Nature Communications, among others). Our laboratory has also reported the first-in-class lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma (Nature). These systems led to the identification of new mechanisms of immune resistance (Nature Medicine) and the generation of nanoparticle-based treatments (Cancer Cell, EMBO Mol Med), with derivatives now being tested in clinical trials. Our ultimate objective is to improve the management of patients with otherwise refractory metastatic melanomas.
Publications
SELECT dxsjj_posts.*
FROM dxsjj_posts LEFT JOIN dxsjj_postmeta ON ( dxsjj_posts.ID = dxsjj_postmeta.post_id ) LEFT JOIN dxsjj_postmeta AS mt1 ON ( dxsjj_posts.ID = mt1.post_id AND mt1.meta_key = 'factor_impacto' ) LEFT JOIN dxsjj_postmeta AS mt2 ON ( dxsjj_posts.ID = mt2.post_id ) LEFT JOIN dxsjj_postmeta AS mt3 ON ( dxsjj_posts.ID = mt3.post_id ) LEFT JOIN dxsjj_postmeta AS mt4 ON ( dxsjj_posts.ID = mt4.post_id )
WHERE 1=1 AND (
(
dxsjj_postmeta.meta_key = 'factor_impacto'
OR
mt1.post_id IS NULL
)
AND
mt2.meta_key = 'autores'
AND
( mt3.meta_key = 'id_grupos' AND mt3.meta_value LIKE '{abfcdebe51853cc10ebf069bcb23cf1409b88aafeb13c444e486081f6e276f49}50006484{abfcdebe51853cc10ebf069bcb23cf1409b88aafeb13c444e486081f6e276f49}' )
AND
( mt4.meta_key = 'anyo' AND CAST(mt4.meta_value AS SIGNED) >= '2018' )
) AND dxsjj_posts.post_type = 'cnio_publication' AND ((dxsjj_posts.post_status = 'publish'))
GROUP BY dxsjj_posts.ID
ORDER BY CAST(mt4.meta_value AS SIGNED) DESC, CAST(dxsjj_postmeta.meta_value AS SIGNED) DESC, CAST(mt2.meta_value AS CHAR) ASC
- Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S (2023). T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.. Immunity 56, 143-161. CNIO Publication.
- Marine JC, Soengas MS (2022). Cell position matters in tumour development. Nature 604, 248-250. CNIO Publication.
- Meçe O, Houbaert D, Sassano ML, Durré T, Maes H, Schaaf M, More S, Ganne M, García-Caballero M, Borri M, Verhoeven J, Agrawal M, Jacobs K, Bergers G, Blacher S, Ghesquière B, Dewerchin M, Swinnen JV, Vinckier S, Soengas MS, Carmeliet P, Noël A, Agostinis P (2022). Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nat Commun 13, 2760. CNIO Publication.
- Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G (2021). Melanoma models for the next generation of therapies. Cancer Cell 39, 610-631. CNIO Publication.
- Olmeda D, Cerezo-Wallis D, Castellano-Sanz E, García-Silva S, Peinado H, Soengas MS (2021). Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles. Adv Drug Deliver Rev 175, 113833. CNIO Publication.
- Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res 27, 2678-2697. CNIO Publication.
- Olmeda D, Cerezo-Wallis D, Mucientes C, Calvo TG, Cañón E, Alonso-Curbelo D, Ibarz N, Muñoz J, Rodriguez-Peralto JL, Ortiz-Romero P, Ortega S, Soengas MS. (2021). Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Mol Med 13, e12924. CNIO Publication.
Open Access - Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS. (2020). Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med 26, 1865-1877. CNIO Publication.
- Lund AW, Soengas MS (2020). Lymph: (Fe)rrying Melanoma to Safety. Cancer Cell 38, 446-448. CNIO Publication.
- Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, Alonso-Curbelo D, Cifdaloz M, Perez-Guijarro E, Gómez-López G, Ximenez-Embun P, Muñoz J, Megias D, Olmeda D, Moscat J, Ortiz-Romero PL, Rodríguez-Peralto JL, Soengas MS. (2019). p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.. Cancer Cell 35, 46-63. CNIO Publication.
- Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, Alonso-Curbelo D, Cifdaloz M, Perez-Guijarro E, Gómez-López G, Ximenez-Embun P, Muñoz J, Megias D, Olmeda D, Moscat J, Ortiz-Romero PL, Rodríguez-Peralto JL, Soengas MS (2019). p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell 35, 46-63. CNIO Publication.
- Bagati A, Moparthy S, Fink EE, Bianchi-Smiraglia A, Yun DH, Kolesnikova M, Udartseva OO, Wolff DW, Roll MV, Lipchick BC, Han Z, Kozlova NI, Jowdy P, Berman AE, Box NF, Rodriguez C, Bshara W, Kandel ES, Soengas MS, Paragh G, Nikiforov MA (2019). KLF9-dependent ROS regulate melanoma progression in stage-specific manner. Oncogene 38, 3585-3597. CNIO Publication.
- Olmeda D, Cerezo-Wallis D, Calvo TG, Alonso-Curbelo D, Cañón E, Ibarz N, Muñoz J, Ortega S, Soengas MS (2019). Antimetastatic dsRNA mimics identified by live imaging of pathogenic neolymphangiogenes. BioRivx (in press). CNIO Publication.
- García-Rodríguez S, Rosal-Vela A, Botta D, Cumba Garcia LM, Zumaquero E, Prados-Maniviesa V, Cerezo-Wallis D, Lo Buono N, Robles-Guirado JÁ, Guerrero S, González-Paredes E, Andrés-León E, Corbí Á, Mack M, Koch-Nolte F, Merino R, Zubiaur M, Lund FE, Sancho J (2018). CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism. Sci Rep 8, 3357. CNIO Publication. Open Access
